Cemiplimab-Rwlc
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Trial Timeline
Oct 22, 2021 → Mar 1, 2028
NCT ID
NCT04975152About Cemiplimab-Rwlc
Cemiplimab-Rwlc is a phase 1 stage product being developed by Sanofi for Merkel Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04975152. Target conditions include Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04975152 | Phase 1 | Active |
Competing Products
20 competing products in Merkel Cell Carcinoma